Literature DB >> 21188465

Everolimus-related organizing pneumonia: a report establishing causality.

Justine Frija1, Dominique Joly, Bertrand Knebelmann, Daniel Dusser, Pierre-Régis Burgel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21188465     DOI： 10.1007/s10637-010-9624-y

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  17 in total

1.  Everolimus-associated interstitial pneumonitis in a patient with a heart transplant.

Authors:  Sascha David; Philipp Kümpers; Hoen Shin; Hermann Haller; Danilo Fliser
Journal:  Nephrol Dial Transplant       Date:  2007-08-27       Impact factor: 5.992

2.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

3.  Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

Authors:  Laure Champion; Marc Stern; Dominique Israël-Biet; Marie-France Mamzer-Bruneel; Marie-Noëlle Peraldi; Henri Kreis; Raphaël Porcher; Emmanuel Morelon
Journal:  Ann Intern Med       Date:  2006-04-04       Impact factor: 25.391

Review 4.  Interstitial lung disease induced by drugs and radiation.

Authors:  Philippe Camus; Annlyse Fanton; Philippe Bonniaud; Clio Camus; Pascal Foucher
Journal:  Respiration       Date:  2004 Jul-Aug       Impact factor: 3.580

5.  Everolimus-related pulmonary toxicity in heart transplant recipients.

Authors:  Victor Expósito; Jose A Vázquez de Prada; Jose J Gómez-Román; Francisco González-Vilchez; Miguel Llano-Cardenal; Tamara García-Camarero; Mónica Fernández-Valls; Javier Ruano; Rafael Martín-Durán
Journal:  J Heart Lung Transplant       Date:  2008-05-19       Impact factor: 10.247

6.  Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.

Authors:  A Rodríguez-Moreno; N Ridao; P García-Ledesma; N Calvo; I Pérez-Flores; M Marques; A Barrientos; A I Sánchez-Fructuoso
Journal:  Transplant Proc       Date:  2009 Jul-Aug       Impact factor: 1.066

7.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Authors:  Anne O'Donnell; Sandrine Faivre; Howard A Burris; Daniel Rea; Vassiliki Papadimitrakopoulou; Nicholas Shand; Heidi A Lane; Katharine Hazell; Ulrike Zoellner; John M Kovarik; Cathryn Brock; Suzanne Jones; Eric Raymond; Ian Judson
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

8.  Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

Authors:  Susan L Ellard; Mark Clemons; Karen A Gelmon; Brian Norris; Hagen Kennecke; Stephen Chia; Kathleen Pritchard; Andrea Eisen; Ted Vandenberg; Marianne Taylor; Eric Sauerbrei; Moshe Mishaeli; David Huntsman; Wendy Walsh; Martin Olivo; Lynn McIntosh; Lesley Seymour
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

9.  Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation.

Authors:  C Agost Carreño; M Gadea
Journal:  Transplant Proc       Date:  2007-04       Impact factor: 1.066

10.  Severe everolimus-associated pneumonitis in a renal transplant recipient.

Authors:  Simona Alexandru; Alberto Ortiz; Sonia Baldovi; Jose Maria Milicua; Elena Ruíz-Escribano; Jesús Egido; Juan José Plaza
Journal:  Nephrol Dial Transplant       Date:  2008-07-25       Impact factor: 5.992
View more
  1 in total

Review 1.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.